Shares of Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) fell 2.2% during mid-day trading on Monday . The company traded as low as $3.91 and last traded at $3.91. 548 shares were traded during trading, a decline of 93% from the average session volume of 7,550 shares. The stock had previously closed at $4.00.
Innovent Biologics Trading Down 2.2 %
The stock’s 50-day moving average is $4.62 and its 200-day moving average is $5.11.
About Innovent Biologics
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Featured Articles
- Five stocks we like better than Innovent Biologics
- How to invest in marijuana stocks in 7 steps
- Sizing Up a New Opportunity for NVIDIA Investors
- Insider Trades May Not Tell You What You Think
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Energy and Oil Stocks Explained
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
